Back to results
US 2023/0414577 A1Published application
Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
AssigneePerfuse Therapeutics, Inc.
InventorsCheng-Wen Lin, Angela Dawn Glendenning, Sevgi Gurkan
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a biodegradable ocular implant comprising a biodegradable polymer containing a compound such as Edonentan, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treatment of ocular diseases with the biodegradable ocular implant and methods of preparation of the same.
Claims23
A biodegradable ocular implant comprising:
- a biodegradable polymer containing a compound incorporated therein, wherein:
- the compound is a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- the concentration of the compound in the biodegradable polymer is about 45% w/w;
- and the biodegradable polymer is selected from the group consisting of:
- (b) [about 20% of RG503]:[about 20% of RG502]:[about 60% of RG753S];
- and
- (c) [about 30% of RG503]:[about 20% of RG502]:[about 30% of RG753S][about 20% of R203S], wherein:
- said RG503 or RG502 is a poly(D,L-lactide-co-glycolide) synthesized at about 50:50 ratio of lactide to glycolide, said RG753S is a poly(D,L-lactide-co-glycolide) synthesized at about 75:25 ratio of lactide to glycolide, and said R203S is a poly(D,L-lactide).
6 more elements
A biodegradable ocular implant comprising a biodegradable polymer containing a compound incorporated therein, wherein:
- the compound is a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- the concentration of the compound in the biodegradable polymer is about 45% w/w;
- and the biodegradable polymer is [about 20% of RG503]:[about 20% of RG502]:[about 60% of RG753S], wherein said RG503 or RG502 is a poly(D,L-lactide-co-glycolide) synthesized at about 50:50 ratio of lactide to glycolide, and said RG753S is a poly(D,L-lactide-co-glycolide) synthesized at about 75:25 ratio of lactide to glycolide.
1 more element
A biodegradable ocular implant comprising:
- a biodegradable polymer containing a compound incorporated therein, wherein:
- the compound is a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- the concentration of the compound in the biodegradable polymer is about 45% w/w;
- and the biodegradable polymer is [about 30% of RG503]:[about 20% of RG502]:[about 30% of RG753S]:[about 20% of R203S], wherein said RG503 or RG502 is a poly(D,L-lactide-co-glycolide) synthesized at about 50:50 ratio of lactide to glycolide, said RG753S is a poly(D,L-lactide-co-glycolide) synthesized at about 75:25 ratio of lactide to glycolide, and said R203S is a poly(D,L-lactide).
2 more elements
Dependencies are inferred from the claim text.